These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 20642825)

  • 21. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
    Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.
    Sheng L; Xiong M; Li C; Meng X
    Pathol Oncol Res; 2014 Jul; 20(3):541-8. PubMed ID: 24327315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of multidrug resistance in feline lymphoma cells.
    Okai Y; Nakamura N; Matsushiro H; Kato H; Setoguchi A; Yazawa M; Okuda M; Watari T; Hasegawa A; Tsujimoto H
    Am J Vet Res; 2000 Sep; 61(9):1122-7. PubMed ID: 10976746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
    Qi X; Chang Z; Song J; Gao G; Shen Z
    Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo.
    Shi Z; Liang YJ; Chen ZS; Wang XW; Wang XH; Ding Y; Chen LM; Yang XP; Fu LW
    Cancer Biol Ther; 2006 Jan; 5(1):39-47. PubMed ID: 16319528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of P-glycoprotein-mediated multidrug resistance by novel curcumin analogues in paclitaxel-resistant human breast cancer cells.
    Gao L; Zhao P; Li Y; Yang D; Hu P; Li L; Cheng Y; Yao H
    Biochem Cell Biol; 2020 Aug; 98(4):484-491. PubMed ID: 31967866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
    Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
    Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining MDR1/P-glycoprotein expression in breast cancer.
    Faneyte IF; Kristel PM; van de Vijver MJ
    Int J Cancer; 2001 Jul; 93(1):114-22. PubMed ID: 11391630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice.
    Zhai BJ; Shao ZY; Zhao CL; Hu K; Wu F
    World J Gastroenterol; 2006 Nov; 12(41):6614-9. PubMed ID: 17075973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro.
    Pan GD; Yang JQ; Yan LN; Chu GP; Liu Q; Xiao Y; Yuan L
    World J Gastroenterol; 2009 Jan; 15(4):431-40. PubMed ID: 19152447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line.
    Cheng J; Cheng L; Chen B; Xia G; Gao C; Song H; Bao W; Guo Q; Zhang H; Wang X
    Int J Nanomedicine; 2012; 7():2843-52. PubMed ID: 22745547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
    Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
    J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells.
    Daschner PJ; Ciolino HP; Plouzek CA; Yeh GC
    Breast Cancer Res Treat; 1999 Feb; 53(3):229-40. PubMed ID: 10369069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARgamma activation by troglitazone.
    Chen Q; Zhou J; Jiang C; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):326-31. PubMed ID: 20556576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
    Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
    Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.